Appendix 4E & Annual Report to 30 June 2026
Filed with ASX · · 56 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue driven by higher grant income and R&D tax incentives, despite a reported loss for the year. EMvision's pivotal trial for its portable brain scanner, emu™, is progressing well, with strong recruitment at leading stroke centers. The company remains focused on advancing its First Responder program and aims to complete the pivotal trial and FDA submission in the upcoming year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- Aeromedical Study De-Risks Rural & Remote Stroke Use Cases
- EMVision to Receive $1.17M IGP Grant Instalment
- emu Pivotal Trial Expansion Adds Acute Ischaemia Detection
- $3.8m R&D Rebate Received & Overseas Finding Approved
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
Later from EMvision Medical Devices
- emu Pivotal Trial Recruitment Surpasses 200 Patients
- emu Regional Benefits Study Advancing
- First Responder Successfully Trialled with MSU
- $4.3m Non-Dilutive R&D Tax Rebate Received
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices